GLP-1 Clinical Relevance #50Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Meta-AnalysisSystematic ReviewCardiovascular OutcomesGLP-1 Receptor AgonistCardiologyAdults with ObesityWeight ManagementIncretin EffectCardiovascular Risk ReductionMetabolic MedicineCardiometabolic...
GLP-1 Receptor Agonist Evidence: Muscle Loss Risks
GLP-1 Clinical Relevance #47Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Systematic ReviewMeta-AnalysisObesityMuscle Mass LossSemaglutideTirzepatideLiraglutideGLP-1 Receptor AgonistEndocrinologyAdults with ObesityLean Body MassIncretin-Based Therapy Why...
GLP-1 Receptor Agonist Randomized Trial: Muscle Loss Risk
GLP-1 Clinical Relevance #44Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic Meta-AnalysisRandomized Controlled TrialObesity TreatmentSemaglutideLiraglutideGLP-1 Receptor AgonistEndocrinologyAdults with ObesityMuscle Mass LossBody Composition OutcomesLean Mass PreservationWeight Loss...
GLP-1 Receptor Agonist Weight Loss: Muscle Loss Risks
GLP-1 Clinical Relevance #49Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Meta-AnalysisRandomized Controlled TrialObesity TreatmentSemaglutideLiraglutideGLP-1 Receptor AgonistEndocrinologyAdults with ObesityLean Mass PreservationMuscle Loss RiskBody...
“Over 70% Of Studies Back Medical Cannabis In Cancer Treatment” “A sweeping meta …
✦ New CED Clinical Relevance #76Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic OncologyPain ManagementNauseaAppetiteMeta-Analysis Why This MattersMeta-analyses of cannabis in oncology provide the strongest level of...
Cannabinoid Clinical Trials: Anxiety & Tourette Review
Clinical Takeaway Cannabinoid formulations, including CBD and THC-containing products, show measurable reductions in anxiety symptoms across multiple disorder types, based on pooled data from randomized and observational studies. Evidence supports modest but...
GLP-1 Receptor Agonist Evidence: 20% Heart Attack Risk Drop
GLP-1 Clinical Relevance #51Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic GLP-1 Cardiovascular BenefitsMedicare GLP-1 CoverageOzempic Heart ProtectionSemaglutide Clinical DataWegovy Medicare Access Why...
Cannabis and Schizophrenia: Meta-Analysis Finds Roughly Threefold Risk Elevation, but Causation Remains Contested
Cannabinoids likely contribute to chronic psychotic events and schizophrenia, especially if taken during adolescence. This effect likely increases with a high cannabis THC concentration and increased frequency of cannabis use, and is stronger in males than in females.
Cannabis Users Need More Propofol, But Confounders Cloud the Evidence
Propofol requirements were significantly higher in cannabis users, who required an average additional dose of 47.33 mg compared to non-users. Subgroup analyses revealed that cannabis users undergoing general anesthesia needed an additional 30.57 mg intraoperatively, while those undergoing sedation for endoscopic procedures required an additional 53.02 mg.
Cannabinoids for Postoperative Pain: A Systematic Review Finds Too Little Evidence to Draw Firm Conclusions
Due to the heterogeneity of methods, it was not possible to carry out meta-analytic evaluations and only qualitative evaluations were feasible.